Morgan Stanley Issues Positive Forecast for Organogenesis (NASDAQ:ORGO) Stock Price

Organogenesis (NASDAQ:ORGO) had its target price raised by Morgan Stanley from $4.00 to $6.00 in a report released on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Organogenesis Stock Up 19.2 %

Shares of NASDAQ ORGO opened at $6.01 on Wednesday. The stock has a market cap of $762.24 million, a P/E ratio of -100.17 and a beta of 1.66. Organogenesis has a 52-week low of $2.17 and a 52-week high of $6.71. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The firm has a 50 day moving average price of $3.56 and a 200 day moving average price of $3.31.

Insider Activity

In other news, CEO Gary S. Gillheeney sold 55,615 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the transaction, the chief executive officer now owns 3,044,779 shares in the company, valued at $10,230,457.44. This represents a 1.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 278,116 shares of company stock worth $991,190 over the last quarter. 36.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ORGO. Captrust Financial Advisors acquired a new position in shares of Organogenesis in the third quarter valued at approximately $36,000. Virtu Financial LLC acquired a new position in Organogenesis during the fourth quarter worth $38,000. Intech Investment Management LLC acquired a new position in Organogenesis during the third quarter worth $43,000. Palumbo Wealth Management LLC acquired a new position in Organogenesis during the fourth quarter worth $65,000. Finally, ProShare Advisors LLC boosted its holdings in Organogenesis by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock worth $65,000 after purchasing an additional 6,689 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.